BY & LARGE PEPTIDES

EQUAL-PARTS RESEARCH BLEND · EXPERIMENTAL

Wolverine Stack 20mg

BPC-157 + TB-500 · 20mg vial



RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY CONSUMPTION · NOT FOR SELF-ADMINISTRATION

A fixed 1:1 blend of two experimental peptides. This 20mg vial contains 10mg BPC-157 and 10mg TB-500, lyophilised together in one vial.

PRICING · PER UNIT

Mix & match any vials — 2–4 −10%, 5+ −15%

RETAIL 1 UNIT	2–4 −10%	5+ −15%
R800	R720	R680

HOW IT WORKS

BPC-157 has been explored in angiogenesis and fibroblast-signalling models. TB-500 and thymosin beta-4-related research includes actin dynamics and cell migration. Most evidence is preclinical.

RESEARCH CONTEXT

Reviews describe largely unvalidated human findings for BPC-157 and a lack of human orthopaedic data for TB-500. Evidence for the combined blend is even more limited.

VIAL CONTENTS & HANDLING

- 10mg BPC-157
- 10mg TB-500
- 20mg total · 1:1 lyophilised blend

Quality & sourcing. Sourced from established manufacturers who test using HPLC analysis. COA available on request — **ask us on WhatsApp ↗**

Storage: keep unopened lyophilised vials in a cool, dark place. Once reconstituted, store in the fridge at 2–8°C and use within 2 months.

RESEARCH REFERENCE DOSAGE

20mg vial · 3ml water · 6.67mg/ml

LEVEL	AMOUNT	U100 UNITS	FREQUENCY
Beginner	250mcg total	**3.75 units**	Once daily · 4 weeks · morning
Intermediate	500mcg total	**7.5 units**	Once daily · 4–6 weeks · morning
Advanced	1mg total	**15 units**	Once daily · 4–6 weeks · morning, or 500mcg twice daily

Fixed 3ml · U100 device (1 unit = 0.01ml). Amounts are total blend; each component is half. Advanced alternative: 500mcg = 7.5 units per administration, twice daily. Research reference only.

Dosing status: No established human dosing standard or evidence-based beginner schedule for this blend.

REFERENCES

- PubMed — Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- PubMed — Human evidence for BPC-157 in orthopaedic and regenerative medicine